{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T00:22:41Z","timestamp":1793751761905,"version":"4.6.1"},"reference-count":539,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jhep.2024.04.031","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T07:21:24Z","timestamp":1717744884000},"page":"492-542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2263,"title":["EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)"],"prefix":"10.1016","volume":"81","author":[{"given":"Frank","family":"Tacke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Wai-Sun Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Ratziu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Bugianesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Francque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shira","family":"Zelber-Sagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Roden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fritz","family":"Schick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannele","family":"Yki-J\u00e4rvinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Gastaldelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Vettor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Fr\u00fchbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dror","family":"Dicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10319","key":"10.1016\/j.jhep.2024.04.031_bib1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","article-title":"The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality","volume":"399","author":"Karlsen","year":"2022","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib2","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib3","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib4","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jhep.2024.01.014","article-title":"Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease","volume":"80","author":"Younossi","year":"2024","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jhep.2018.10.011","article-title":"Clinical practice guidelines of the European association for the study of the liver - advancing methodology but preserving practicability","volume":"70","author":"Cornberg","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.031_bib6","unstructured":"\u201cThe Oxford Levels of Evidence 2\u201d. Oxford Centre for Evidence-Based Medicine. [Available from: https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/ocebm-levels-of-evidence]."},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib7","first-page":"281","article-title":"[Principles and practice of mass screening for disease]","volume":"65","author":"Wilson","year":"1968","journal-title":"Bol Oficina Sanit Panam"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib8","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S2468-1253(23)00443-0","article-title":"Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study","volume":"9","author":"Israelsen","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib9","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.jhep.2023.08.018","article-title":"Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: nationwide multigenerational cohort study","volume":"79","author":"Ebrahimi","year":"2023","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib10","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/hep.30857","article-title":"Nonalcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B","volume":"71","author":"Choi","year":"2020","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.cld.2013.09.006","article-title":"The impact of obesity and metabolic syndrome on alcoholic liver disease","volume":"18","author":"Chiang","year":"2014","journal-title":"Clin Liver Dis"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib12","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis\u00a0(NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis","volume":"8","author":"Quek","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jhep.2023.03.040","article-title":"Global incidence of non-alcoholic fatty liver disease: a systematic review and meta-analysis of 63 studies and 1,201,807 persons","volume":"79","author":"Le","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.031_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155642","article-title":"Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States","volume":"146","author":"Golabi","year":"2023","journal-title":"Metabolism"},{"issue":"11","key":"10.1016\/j.jhep.2024.04.031_bib16","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1136\/gutjnl-2023-330110","article-title":"Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis","volume":"72","author":"En Li Cho","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2024.04.031_bib17","doi-asserted-by":"crossref","DOI":"10.2337\/dc23-1937","article-title":"Metabolic syndrome traits increase the risk of major adverse liver outcomes in type 2 diabetes","author":"Shang","year":"2024","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.jhep.2024.04.031_bib18","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","article-title":"Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort","volume":"70","author":"Simon","year":"2021","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-137-1-200207020-00006","article-title":"Updated definitions of healthy ranges for serum alanine aminotransferase levels","volume":"137","author":"Prati","year":"2002","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.jhep.2024.04.031_bib20","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1002\/hep4.1794","article-title":"Definition of healthy ranges for alanine aminotransferase levels: a 2021 update","volume":"5","author":"Valenti","year":"2021","journal-title":"Hepatol Commun"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ajg.2016.517","article-title":"ACG clinical guideline: evaluation of abnormal liver chemistries","volume":"112","author":"Kwo","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib22","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1210\/jc.2015-1966","article-title":"High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels","volume":"100","author":"Portillo-Sanchez","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/joim.13343","article-title":"Risk for hepatic and extra-hepatic outcomes in nonalcoholic fatty liver disease","volume":"292","author":"Hagstrom","year":"2022","journal-title":"J Intern Med"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib24","article-title":"Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis","volume":"9","author":"Liu","year":"2019","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.jhep.2024.04.031_bib25","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis","volume":"6","author":"Mantovani","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib26","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jceh.2022.11.006","article-title":"Hepatic, extra-hepatic outcomes and causes of mortality in NAFLD - an umbrella overview of systematic review of meta-analysis","volume":"13","author":"Xiao","year":"2023","journal-title":"J Clin Exp Hepatol"},{"issue":"9","key":"10.1016\/j.jhep.2024.04.031_bib27","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/apt.17424","article-title":"Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic comorbidities","volume":"57","author":"Wijarnpreecha","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.jhep.2024.04.031_bib28","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1016\/j.cgh.2021.09.021","article-title":"A meta-analysis on the global prevalence,\u00a0risk factors and screening of coronary heart disease in nonalcoholic\u00a0fatty liver disease","volume":"20","author":"Toh","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.04.031_bib29","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/gutjnl-2022-327672","article-title":"Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals","volume":"72","author":"Mantovani","year":"2023","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib30","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/gutjnl-2021-324191","article-title":"Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib32","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"10","key":"10.1016\/j.jhep.2024.04.031_bib33","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib34","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease - a global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"issue":"13","key":"10.1016\/j.jhep.2024.04.031_bib35","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000010214","article-title":"Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)","volume":"97","author":"Golabi","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173499","article-title":"Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States","volume":"12","author":"Le","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib37","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/hep.32207","article-title":"High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population","volume":"75","author":"Vilar-Gomez","year":"2022","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib38","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/hep4.1831","article-title":"Community socioeconomic deprivation predicts nonalcoholic steatohepatitis","volume":"6","author":"Giammarino","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2024.04.031_bib39","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejim.2023.07.039","article-title":"Relationships between education and non-alcoholic fatty liver disease","volume":"118","author":"Koutny","year":"2023","journal-title":"Eur J Intern Med"},{"issue":"i-xii","key":"10.1016\/j.jhep.2024.04.031_bib40","first-page":"1","article-title":"Obesity: preventing and managing the global epidemic. Report of a WHO consultation","volume":"894","year":"2000","journal-title":"World Health Organ Tech Rep Ser"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib41","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7570\/jomes23031","article-title":"Diagnosis of obesity: 2022 update of clinical practice guidelines for obesity by the Korean society for the study of obesity","volume":"32","author":"Haam","year":"2023","journal-title":"J Obes Metab Syndr"},{"issue":"16","key":"10.1016\/j.jhep.2024.04.031_bib42","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib43","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/hep.21327","article-title":"Long-term follow-up of patients with NAFLD and elevated liver enzymes","volume":"44","author":"Ekstedt","year":"2006","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhep.2024.04.031_bib44","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c912","article-title":"Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study","volume":"340","author":"Liu","year":"2010","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib45","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/hep.24418","article-title":"Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis","volume":"54","author":"Berzigotti","year":"2011","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib46","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ijc.26338","article-title":"Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults","volume":"131","author":"Borena","year":"2012","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib47","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/jhep.2002.33713","article-title":"Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?","volume":"36","author":"Nair","year":"2002","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib48","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.gastro.2015.03.044","article-title":"Obesity early in adulthood increases risk but does not affect outcomes of hepatocellular carcinoma","volume":"149","author":"Hassan","year":"2015","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib49","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jhep.2022.11.010","article-title":"A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes","volume":"78","author":"Ajmera","year":"2023","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib50","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib51","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A global view of the interplay between non-alcoholic fatty\u00a0liver disease and diabetes","volume":"10","author":"Stefan","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.jhep.2024.04.031_bib52","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.2337\/dc22-2048","article-title":"High prevalence of NASH and advanced fibrosis in type 2 diabetes: a prospective study of 330 outpatients undergoing liver biopsies for elevated ALT, using a low threshold","volume":"46","author":"Castera","year":"2023","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib53","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/j.gastro.2023.04.025","article-title":"Fibrosis progression rate in biopsy-proven nonalcoholic fatty liver disease among people with diabetes versus people without diabetes: a multicenter study","volume":"165","author":"Huang","year":"2023","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib54","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/hep.31845","article-title":"Cancer risk in patients with biopsy-confirmed nonalcoholic fatty liver disease: a population-based cohort study","volume":"74","author":"Simon","year":"2021","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib55","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/hep.30858","article-title":"Diabetes is associated with increased\u00a0risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease","volume":"71","author":"Yang","year":"2020","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib56","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12916-019-1321-x","article-title":"Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts","volume":"17","author":"Alexander","year":"2019","journal-title":"BMC Med"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib57","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.31014","article-title":"Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"11","key":"10.1016\/j.jhep.2024.04.031_bib58","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1007\/s00125-022-05769-4","article-title":"Phenotypic and genetic classification of diabetes","volume":"65","author":"Deutsch","year":"2022","journal-title":"Diabetologia"},{"issue":"11","key":"10.1016\/j.jhep.2024.04.031_bib59","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1007\/s00125-021-05625-x","article-title":"A novel diabetes typology: towards precision diabetology from pathogenesis to treatment","volume":"65","author":"Herder","year":"2022","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib60","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S2213-8587(23)00329-7","article-title":"Analysis of type 2 diabetes heterogeneity with a tree-like representation: insights from the prospective German Diabetes Study and the LURIC cohort","volume":"12","author":"Schon","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib61","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41591-020-1116-9","article-title":"Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes","volume":"27","author":"Wagner","year":"2021","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib62","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.04.031_bib63","article-title":"Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects: a population-based study","volume":"13","author":"Julian","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"10.1016\/j.jhep.2024.04.031_bib64","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1097\/MEG.0000000000000973","article-title":"The association of nonalcoholic steatohepatitis and obstructive sleep apnea","volume":"29","author":"Asfari","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib65","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jhep.2011.04.022","article-title":"Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese","volume":"56","author":"Aron-Wisnewsky","year":"2012","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib66","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/liv.14279","article-title":"Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis","volume":"40","author":"Sarkar","year":"2020","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib67","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/GME.0000000000002133","article-title":"Menopause is associated with increased prevalence of nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"30","author":"Jaroenlapnopparat","year":"2023","journal-title":"Menopause"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib68","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/hep.26761","article-title":"Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis","volume":"59","author":"Yang","year":"2014","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib69","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/hep.27097","article-title":"The influence of menopause on the development of hepatic fibrosis in nonobese women with nonalcoholic fatty liver disease","volume":"60","author":"Yoneda","year":"2014","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib70","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jhep.2021.02.034","article-title":"Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort","volume":"75","author":"Harrison","year":"2021","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib71","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.cgh.2017.09.041","article-title":"Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: a systematic review and meta-analysis","volume":"16","author":"Rich","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.jhep.2024.04.031_bib72","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/s41416-018-0007-z","article-title":"Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: the Liver Cancer Pooling Project","volume":"118","author":"Petrick","year":"2018","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.jhep.2024.04.031_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12093336","article-title":"Smoking increases the risk of hepatocellular carcinoma and cardiovascular disease in patients with metabolic-associated fatty liver disease","volume":"12","author":"Yoo","year":"2023","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib74","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/jebm.12270","article-title":"Cigarette smoking as a risk factor for the development of and mortality from hepatocellular carcinoma: an updated systematic review of 81 epidemiological studies","volume":"10","author":"Abdel-Rahman","year":"2017","journal-title":"J Evid Based Med"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib75","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jhep.2022.08.030","article-title":"Alcohol consumption and metabolic syndrome: clinical and epidemiological impact on liver disease","volume":"78","author":"\u00c5berg","year":"2023","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib76","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2022.04.040","article-title":"Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease","volume":"77","author":"Staufer","year":"2022","journal-title":"J Hepatol"},{"issue":"10152","key":"10.1016\/j.jhep.2024.04.031_bib77","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0140-6736(18)31310-2","article-title":"Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"392","year":"2018","journal-title":"Lancet"},{"issue":"10347","key":"10.1016\/j.jhep.2024.04.031_bib78","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(22)00847-9","article-title":"Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020","volume":"400","year":"2022","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.jhep.2024.04.031_bib79","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJM199712113372401","article-title":"Alcohol consumption and mortality among middle-aged and elderly U.S. adults","volume":"337","author":"Thun","year":"1997","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib80","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1465-3362.2009.00052.x","article-title":"A healthy dose of scepticism: four good reasons to think again about protective effects of alcohol on coronary heart disease","volume":"28","author":"Chikritzhs","year":"2009","journal-title":"Drug Alcohol Rev"},{"issue":"7","key":"10.1016\/j.jhep.2024.04.031_bib81","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1136\/jech.2007.065607","article-title":"Does drinking pattern modify the effect of alcohol on the risk of coronary heart disease? Evidence from a meta-analysis","volume":"62","author":"Bagnardi","year":"2008","journal-title":"J Epidemiol Community Health"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib82","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/add.13757","article-title":"The relationship between different dimensions of alcohol use and the burden of disease-an update","volume":"112","author":"Rehm","year":"2017","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib83","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/acer.14271","article-title":"Interaction between alcohol use and metabolic risk factors for liver disease: a critical review of epidemiological studies","volume":"44","author":"\u00c5berg","year":"2020","journal-title":"Alcohol Clin Exp Res"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib84","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1002\/hep.29631","article-title":"Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population","volume":"67","author":"Aberg","year":"2018","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib85","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/hep.510250120","article-title":"Excess weight risk factor for alcoholic liver disease","volume":"25","author":"Naveau","year":"1997","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhep.2024.04.031_bib86","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c1240","article-title":"Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies","volume":"340","author":"Hart","year":"2010","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.jhep.2024.04.031_bib87","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.cgh.2018.11.033","article-title":"Effects of alcohol consumption and metabolic syndrome on mortality in patients with nonalcoholic and\u00a0alcohol-related fatty liver disease","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib88","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/hep.30226","article-title":"Effect of alcohol consumption on survival in nonalcoholic fatty liver disease: a national prospective cohort study","volume":"70","author":"Hajifathalian","year":"2019","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib89","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/gutjnl-2013-305718","article-title":"Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease: a meta-analysis of 43 175 individuals","volume":"63","author":"Sookoian","year":"2014","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib90","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jhep.2012.03.024","article-title":"Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD)","volume":"57","author":"Dunn","year":"2012","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib91","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/hep.30864","article-title":"Risks of light and moderate alcohol use in fatty liver disease: follow-up of population cohorts","volume":"71","author":"Aberg","year":"2020","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib92","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-049767","article-title":"Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis","volume":"12","author":"Jarvis","year":"2022","journal-title":"BMJ Open"},{"issue":"10","key":"10.1016\/j.jhep.2024.04.031_bib93","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.14309\/ajg.0000000000000340","article-title":"Alcohol consumption and risk of liver cirrhosis: a systematic review and meta-analysis","volume":"114","author":"Roerecke","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib94","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jhep.2014.12.005","article-title":"Alcohol drinking pattern and risk of alcoholic liver cirrhosis: a prospective cohort study","volume":"62","author":"Askgaard","year":"2015","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib95","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/S2468-2667(18)30230-5","article-title":"Alcohol drinking patterns and liver cirrhosis risk: analysis of the prospective UK Million Women Study","volume":"4","author":"Simpson","year":"2019","journal-title":"Lancet Public Health"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib96","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/aje\/kws252","article-title":"Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study","volume":"177","author":"Loomba","year":"2013","journal-title":"Am J Epidemiol"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib97","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jhep.2004.10.005","article-title":"Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma","volume":"42","author":"Marrero","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.031_bib98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.alcohol.2020.07.010","article-title":"Moderate alcohol consumption is not associated with subclinical cardiovascular damage but with hepatic fibrosis in non-alcoholic fatty liver disease","volume":"89","author":"Kashiwagi","year":"2020","journal-title":"Alcohol"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib99","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1053\/j.gastro.2017.08.012","article-title":"Alcohol use and cardiovascular disease risk in patients with nonalcoholic fatty liver disease","volume":"153","author":"VanWagner","year":"2017","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib100","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jhep.2022.11.013","article-title":"Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohort","volume":"78","author":"Louvet","year":"2023","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib101","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.23527","article-title":"The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis","volume":"51","author":"Ascha","year":"2010","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib102","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1053\/j.gastro.2018.03.038","article-title":"Improved diet quality associates with reduction in liver fat, particularly in individuals with high genetic risk scores for nonalcoholic fatty liver disease","volume":"155","author":"Ma","year":"2018","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.jhep.2024.04.031_bib103","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/s41430-020-0563-1","article-title":"Differences in the association of diet quality with body fat distribution between men and women","volume":"74","author":"Maskarinec","year":"2020","journal-title":"Eur J Clin Nutr"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib104","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/ije\/dyab174","article-title":"Ultra-processed food consumption and the risk of non-alcoholic fatty liver disease in the tianjin chronic low-grade systemic inflammation and health cohort study","volume":"51","author":"Zhang","year":"2022","journal-title":"Int J Epidemiol"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib105","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/hep.30362","article-title":"Dietary patterns and risk of hepatocellular carcinoma among U.S. Men and women","volume":"70","author":"Ma","year":"2019","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib106","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/hep4.1313","article-title":"High-quality diets are associated with reduced risk of hepatocellular carcinoma and chronic liver disease: the multiethnic cohort","volume":"3","author":"Bogumil","year":"2019","journal-title":"Hepatol Commun"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib107","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/hep.31251","article-title":"Plant-based and animal-based low-carbohydrate diets and risk of hepatocellular carcinoma among US men and women","volume":"73","author":"Liu","year":"2021","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"9","key":"10.1016\/j.jhep.2024.04.031_bib108","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1002\/ijc.33367","article-title":"Quality diet indexes and risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study","volume":"148","author":"Luu","year":"2021","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib109","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clnu.2021.12.014","article-title":"Red meat consumption, obesity, and the risk of nonalcoholic fatty liver disease among women: evidence from mediation analysis","volume":"41","author":"Kim","year":"2022","journal-title":"Clin Nutr"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib110","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1093\/ajcn\/nqaa380","article-title":"Soft drink consumption and risk of nonalcoholic fatty liver disease: results from the Tianjin Chronic Low-Grade Systemic Inflammation and Health (TCLSIH) cohort study","volume":"113","author":"Zhang","year":"2021","journal-title":"Am J Clin Nutr"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib111","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1093\/ije\/dyz146","article-title":"Meat intake and risk of hepatocellular carcinoma in two large US prospective cohorts of women and men","volume":"48","author":"Ma","year":"2019","journal-title":"Int J Epidemiol"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib112","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1001\/jama.2023.12618","article-title":"Sugar-sweetened and artificially sweetened beverages and risk of liver cancer and chronic liver disease mortality","volume":"330","author":"Zhao","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib113","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jhep.2022.01.016","article-title":"Cigarette smoking and liver diseases","volume":"77","author":"Marti-Aguado","year":"2022","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib114","article-title":"Physical activity is associated with reduced risk of liver disease in the prospective UK Biobank cohort","volume":"3","author":"Schneider","year":"2021","journal-title":"JHEP Rep"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib115","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.jhep.2019.12.022","article-title":"Physical activity compared to adiposity and risk of liver-related mortality: results from two prospective, nationwide cohorts","volume":"72","author":"Simon","year":"2020","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib116","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1158\/1055-9965.EPI-20-1201","article-title":"Composite score of healthy lifestyle factors and risk of hepatocellular carcinoma: findings from a prospective cohort study","volume":"30","author":"Luu","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"7","key":"10.1016\/j.jhep.2024.04.031_bib117","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41416-020-0741-x","article-title":"Combined lifestyle factors, incident cancer, and cancer mortality: a systematic review and meta-analysis of prospective cohort studies","volume":"122","author":"Zhang","year":"2020","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib118","doi-asserted-by":"crossref","first-page":"76","DOI":"10.21101\/cejph.a6239","article-title":"International evidence for the effectiveness of the front-of-package nutrition label called Nutri-Score","volume":"29","author":"Andreeva","year":"2021","journal-title":"Cent Eur J Public Health"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib119","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","article-title":"Changing epidemiology, global trends and implications for outcomes of NAFLD","volume":"79","author":"Wong","year":"2023","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib120","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/hep.32633","article-title":"Age and the relative importance of liver-related deaths in nonalcoholic fatty liver disease","volume":"77","author":"Lin","year":"2023","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib121","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"issue":"17","key":"10.1016\/j.jhep.2024.04.031_bib122","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib123","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cgh.2015.07.019","article-title":"Hepatocellular carcinoma in the absence of cirrhosis in United States Veterans is associated with nonalcoholic fatty liver disease","volume":"14","author":"Mittal","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib124","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib125","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib126","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib127","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jhep.2022.10.010","article-title":"Time to focus on chronic liver diseases in the community: a review of primary care hepatology tools, pathways of care and reimbursement mechanisms","volume":"78","author":"Pryke","year":"2023","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.jhep.2024.04.031_bib128","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1136\/gutjnl-2023-330269","article-title":"Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial","volume":"72","author":"Zhang","year":"2023","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib129","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jhep.2019.08.019","article-title":"Transient elastography for screening of liver fibrosis: cost-effectiveness analysis from six prospective cohorts in Europe and Asia","volume":"71","author":"Serra-Burriel","year":"2019","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.jhep.2024.04.031_bib130","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.cgh.2020.04.017","article-title":"Cost effectiveness of different strategies for detecting cirrhosis in patients with nonalcoholic fatty liver disease based on United States health care system","volume":"18","author":"Vilar-Gomez","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"17","key":"10.1016\/j.jhep.2024.04.031_bib131","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006585","article-title":"Cost-effectiveness analysis of ultrasonography screening for nonalcoholic fatty liver disease in metabolic syndrome patients","volume":"96","author":"Phisalprapa","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib132","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1053\/j.gastro.2020.07.050","article-title":"Nashnet. Screening for nonalcoholic fatty liver disease in persons with type 2 diabetes in the United States is cost-effective: a comprehensive cost-utility analysis","volume":"159","author":"Noureddin","year":"2020","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib133","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147237","article-title":"Cost-effectiveness analysis: risk stratification of nonalcoholic fatty liver disease (NAFLD) by the primary care physician using the NAFLD fibrosis score","volume":"11","author":"Tapper","year":"2016","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.jhep.2024.04.031_bib134","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s10620-016-4044-2","article-title":"Screening for nonalcoholic steatohepatitis in individuals with type 2 diabetes: a cost-effectiveness analysis","volume":"61","author":"Corey","year":"2016","journal-title":"Dig Dis Sci"},{"issue":"21","key":"10.1016\/j.jhep.2024.04.031_bib135","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162513","article-title":"Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease","volume":"132","author":"Tamaki","year":"2022","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib136","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest","volume":"46","author":"Vallet-Pichard","year":"2007","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib137","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib138","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib139","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","year":"2021","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.jhep.2024.04.031_bib140","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S2468-1253(23)00017-1","article-title":"Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study","volume":"8","author":"Vali","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib141","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1016\/j.jhep.2024.04.031_bib142","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1097\/MEG.0000000000002641","article-title":"Multicenter validation of FIB-6 as a novel machine learning non-invasive score to rule out liver cirrhosis in biopsy-proven MAFLD","volume":"35","author":"Anushiravani","year":"2023","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"10406","key":"10.1016\/j.jhep.2024.04.031_bib143","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S0140-6736(23)01174-1","article-title":"Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study","volume":"402","author":"Serra-Burriel","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2024.04.031_bib144","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2024.03.017","article-title":"Maf-5 predicts liver fibrosis risk and outcome in the general population with metabolic dysfunction","author":"van Kleef","year":"2024","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib145","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/hep.32545","article-title":"The steatosis-associated fibrosis estimator (SAFE) score: a tool to detect low-risk NAFLD in primary care","volume":"77","author":"Sripongpun","year":"2023","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib146","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1053\/j.gastro.2004.08.052","article-title":"Serum markers detect the presence of liver fibrosis: a cohort study","volume":"127","author":"Rosenberg","year":"2004","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.jhep.2024.04.031_bib147","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/apt.17385","article-title":"Meta-analysis: enhanced liver fibrosis test to identify hepatic fibrosis in chronic liver diseases","volume":"57","author":"Hinkson","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib148","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/hep.30163","article-title":"ADAPT: an algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis","volume":"69","author":"Daniels","year":"2019","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib149","doi-asserted-by":"crossref","first-page":"984","DOI":"10.14309\/ajg.0000000000001059","article-title":"A sequential algorithm combining ADAPT and liver stiffness can stage metabolic-associated fatty liver disease in hospital-based and primary care patients","volume":"116","author":"Eslam","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1016\/j.jhep.2024.04.031_bib150","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1007\/s00261-021-03269-4","article-title":"Liver fibrosis assessment: MR and US elastography","volume":"47","author":"Ozturk","year":"2022","journal-title":"Abdom Radiol (NY)"},{"issue":"32","key":"10.1016\/j.jhep.2024.04.031_bib151","doi-asserted-by":"crossref","first-page":"7236","DOI":"10.3748\/wjg.v22.i32.7236","article-title":"Transient elastography (FibroScan(\u00ae)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease \u2013 Where do we stand?","volume":"22","author":"Mikolasevic","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib152","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/hep.23312","article-title":"Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease","volume":"51","author":"Wong","year":"2010","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib153","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jhep.2022.03.026","article-title":"Impact of non-invasive biomarkers on\u00a0hepatology practice: past, present and future","volume":"76","author":"Anstee","year":"2022","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.jhep.2024.04.031_bib154","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.7150\/thno.40249","article-title":"Quantitative ultrasound approaches for diagnosis and monitoring hepatic steatosis in nonalcoholic fatty liver disease","volume":"10","author":"Pirmoazen","year":"2020","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib155","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/hep.31655","article-title":"Transient versus two-dimensional shear-wave elastography in a multistep strategy to detect advanced fibrosis in NAFLD","volume":"73","author":"Cassinotto","year":"2021","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib156","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/apt.12569","article-title":"Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments","volume":"39","author":"Kwok","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib157","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jhep.2021.04.044","article-title":"Diagnostic accuracy\u00a0of\u00a0elastography and magnetic resonance imaging in patients with\u00a0NAFLD: a systematic review and meta-analysis","volume":"75","author":"Selvaraj","year":"2021","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib158","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.29302","article-title":"Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis","volume":"66","author":"Xiao","year":"2017","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib159","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.cgh.2020.12.016","article-title":"Direct comparison of US and MR elastography for staging liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"20","author":"Imajo","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.jhep.2024.04.031_bib160","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.cgh.2021.09.041","article-title":"Clinical utility of magnetic resonance imaging biomarkers for identifying nonalcoholic steatohepatitis patients at high risk of progression: a multicenter pooled data and meta-analysis","volume":"20","author":"Andersson","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib161","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jhep.2015.10.009","article-title":"Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease","volume":"64","author":"Pavlides","year":"2016","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib162","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1148\/radiol.2021204288","article-title":"Quantification of liver fat content with CT and MRI: state of the art","volume":"301","author":"Starekova","year":"2021","journal-title":"Radiology"},{"issue":"7","key":"10.1016\/j.jhep.2024.04.031_bib163","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1007\/s00330-019-06072-4","article-title":"Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis","volume":"29","author":"Gu","year":"2019","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib164","article-title":"Marked difference in liver fat measured by histology vs. magnetic resonance-proton density fat fraction: a meta-analysis","volume":"6","author":"Qadri","year":"2024","journal-title":"JHEP Rep"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib165","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/mrm.20825","article-title":"Hepatic lipid accumulation in healthy subjects: a comparative study using spectral fat-selective MRI and volume-localized 1H-MR spectroscopy","volume":"55","author":"Machann","year":"2006","journal-title":"Magn Reson Med"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib166","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","article-title":"Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis","volume":"66","author":"Karlas","year":"2017","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib167","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jhep.2021.11.012","article-title":"MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis","volume":"76","author":"Noureddin","year":"2022","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib168","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.jhep.2024.04.031_bib169","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1136\/gutjnl-2020-322976","article-title":"MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis","volume":"70","author":"Jung","year":"2021","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib170","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1053\/j.gastro.2022.06.073","article-title":"Liver stiffness on magnetic resonance elastography and the MEFIB index and liver-related outcomes in nonalcoholic fatty liver disease: a systematic review and meta-analysis of individual participants","volume":"163","author":"Ajmera","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.04.031_bib171","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2024.03.023","article-title":"Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes","author":"Castera","year":"2024","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib172","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.jhep.2022.07.020","article-title":"Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD","volume":"77","author":"Kim","year":"2022","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib173","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jhep.2021.12.031","article-title":"Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events","volume":"76","author":"Boursier","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib174","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S2468-1253(23)00270-4","article-title":"Implementation of a liver health check in people with type 2 diabetes","volume":"9","author":"Abeysekera","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.jhep.2024.04.031_bib175","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.cgh.2018.12.031","article-title":"Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage","volume":"17","author":"Siddiqui","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib176","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1053\/j.gastro.2013.06.057","article-title":"Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"145","author":"Angulo","year":"2013","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib177","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.cgh.2018.11.030","article-title":"Accuracy of noninvasive scoring systems in assessing risk of death and liver-related endpoints in patients with nonalcoholic fatty liver disease","volume":"17","author":"Hagstrom","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib178","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jhep.2016.04.023","article-title":"Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease","volume":"65","author":"Boursier","year":"2016","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib179","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/ajg.2011.327","article-title":"Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma","volume":"107","author":"Kawamura","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib180","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.26156","article-title":"Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States","volume":"57","author":"Kim","year":"2013","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib181","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1053\/j.gastro.2020.12.003","article-title":"The association of histologic and noninvasive tests with adverse clinical and patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis","volume":"160","author":"Younossi","year":"2021","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib182","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.jhep.2021.05.008","article-title":"Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease","volume":"75","author":"Younes","year":"2021","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.jhep.2024.04.031_bib183","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/apt.14990","article-title":"Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease","volume":"48","author":"Munteanu","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"15","key":"10.1016\/j.jhep.2024.04.031_bib184","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jama.2024.1447","article-title":"Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease","volume":"331","author":"Lin","year":"2024","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib185","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.cgh.2020.06.045","article-title":"Monitoring occurrence of liver-related events and survival by transient elastography in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease","volume":"19","author":"Petta","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib186","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1136\/gutjnl-2022-327777","article-title":"Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis","volume":"72","author":"Loomba","year":"2023","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.jhep.2024.04.031_bib187","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S2468-1253(23)00141-3","article-title":"Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis","volume":"8","author":"Mozes","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib188","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.cgh.2014.07.037","article-title":"Significant variations in elastometry measurements made within short-term in patients with chronic liver diseases","volume":"13","author":"Nascimbeni","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib189","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s41747-022-00303-y","article-title":"Variability of noninvasive MRI and biological markers in compensated cirrhosis: insights for assessing disease progression","volume":"6","author":"Bradley","year":"2022","journal-title":"Eur Radiol Exp"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib190","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/jgh.14311","article-title":"Repeating measurements by transient elastography in non-alcoholic fatty liver disease patients with high liver stiffness","volume":"34","author":"Chow","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib191","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jhep.2020.06.007","article-title":"Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease","volume":"73","author":"Hagstrom","year":"2020","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib192","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1053\/j.gastro.2019.09.008","article-title":"Ability of noninvasive scoring systems to identify individuals in the population at risk for severe liver disease","volume":"158","author":"Hagstrom","year":"2020","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib193","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.jhep.2020.02.020","article-title":"Update on NAFLD genetics: from new variants to the clinic","volume":"72","author":"Trepo","year":"2020","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib194","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1053\/j.gastro.2023.01.040","article-title":"PNPLA3 genotype and diabetes identify patients with nonalcoholic fatty liver disease at high risk of incident cirrhosis","volume":"164","author":"Chen","year":"2023","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib195","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2014.02.030","article-title":"Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma","volume":"61","author":"Liu","year":"2014","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib196","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1038\/s41598-019-39998-2","article-title":"Rare pathogenic variants predispose to hepatocellular carcinoma in nonalcoholic fatty liver disease","volume":"9","author":"Pelusi","year":"2019","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.jhep.2024.04.031_bib197","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1038\/s41591-023-02553-8","article-title":"Interaction between estrogen receptor-alpha and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women","volume":"29","author":"Cherubini","year":"2023","journal-title":"Nat Med"},{"issue":"13","key":"10.1016\/j.jhep.2024.04.031_bib198","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1016\/j.cgh.2023.04.024","article-title":"Impact of PNPLA3 rs738409 polymorphism on the development of liver-related events in patients with nonalcoholic fatty liver disease","volume":"21","author":"Rosso","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib199","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","article-title":"The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent","volume":"150","author":"Mancina","year":"2016","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.jhep.2024.04.031_bib200","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A protein-truncating HSD17B13 variant and protection from chronic liver disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib201","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/joim.12719","article-title":"Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver","volume":"283","author":"Dongiovanni","year":"2018","journal-title":"J Intern Med"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib202","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.jhep.2022.03.031","article-title":"Rare ATG7 genetic variants predispose patients to severe fatty liver disease","volume":"77","author":"Baselli","year":"2022","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib203","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1053\/j.gastro.2020.12.023","article-title":"Exome-wide association study on alanine aminotransferase identifies sequence variants in the GPAM and APOE associated with fatty liver disease","volume":"160","author":"Jamialahmadi","year":"2021","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib204","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1056\/NEJMoa2117872","article-title":"Germline mutations in CIDEB and protection against liver disease","volume":"387","author":"Verweij","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib205","article-title":"Machine learning enables new insights into genetic contributions to liver fat accumulation","volume":"1","author":"Haas","year":"2021","journal-title":"Cell Genom"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib206","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jhep.2020.11.024","article-title":"Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores","volume":"74","author":"Bianco","year":"2021","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib207","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.cgh.2021.05.056","article-title":"A polygenic risk score to refine risk stratification and prediction for severe liver disease by clinical fibrosis scores","volume":"20","author":"De Vincentis","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib208","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1002\/hep.32047","article-title":"Emerging role of genomic analysis in clinical evaluation of lean individuals with NAFLD","volume":"74","author":"Vilarinho","year":"2021","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib209","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jhep.2019.01.036","article-title":"Clinical utility of genomic analysis in adults with idiopathic liver disease","volume":"70","author":"Hakim","year":"2019","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib210","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/liv.15185","article-title":"Clinical exome sequencing for diagnosing severe cryptogenic liver disease in adults: a case series","volume":"42","author":"Pelusi","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2024.04.031_bib211","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2023.12.033","article-title":"Prevalence and determinants of liver disease in relatives of Italian patients with advanced MASLD","author":"Pelusi","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.04.031_bib212","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104747","article-title":"Advancing diagnosis and management of liver disease in adults through exome sequencing","volume":"95","author":"Zheng","year":"2023","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib213","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/tpj.2017.45","article-title":"The PNPLA3 I148M variant is\u00a0associated with transaminase elevations in type 2 diabetes patients\u00a0treated with basal insulin peglispro","volume":"18","author":"Pillai","year":"2018","journal-title":"Pharmacogenomics J"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib214","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2022.11.025","article-title":"A phase I\/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis","volume":"78","author":"Mak","year":"2023","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.jhep.2024.04.031_bib215","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1080\/14728222.2021.2018418","article-title":"PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date","volume":"25","author":"Cherubini","year":"2021","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib216","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41574-023-00898-1","article-title":"Inter-organ crosstalk during development and progression of type 2 diabetes mellitus","volume":"20","author":"Xourafa","year":"2024","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib217","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.cld.2023.01.002","article-title":"Metabolic syndrome and its association with nonalcoholic steatohepatitis","volume":"27","author":"Bril","year":"2023","journal-title":"Clin Liver Dis"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib218","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","article-title":"Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals","volume":"70","author":"Mantovani","year":"2021","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.jhep.2024.04.031_bib219","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S2213-8587(19)30187-1","article-title":"Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study","volume":"7","author":"Zaharia","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"10.1016\/j.jhep.2024.04.031_bib220","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1007\/s00125-017-4340-1","article-title":"Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study","volume":"60","author":"Isokuortti","year":"2017","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.jhep.2024.04.031_bib221","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/oby.23503","article-title":"Measuring and estimating insulin resistance in clinical and research settings","volume":"30","author":"Gastaldelli","year":"2022","journal-title":"Obesity (Silver Spring)"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib222","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1210\/clinem\/dgac660","article-title":"Adipose tissue insulin resistance predicts the severity of liver fibrosis in patients with type 2 diabetes and NAFLD","volume":"108","author":"Kalavalapalli","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib223","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/hep.23280","article-title":"Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications","volume":"51","author":"Fabbrini","year":"2010","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib224","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000497124","article-title":"The ABCD of obesity: an EASO position statement on a diagnostic term with clinical and scientific implications","volume":"12","author":"Fr\u00fchbeck","year":"2019","journal-title":"Obes Facts"},{"key":"10.1016\/j.jhep.2024.04.031_bib225","first-page":"S350","article-title":"Visceral fat as a strong and independent risk factor of nonalcoholic fatty liver disease","volume":"48","author":"Kim","year":"2008","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib226","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/gutjnl-2020-323082","article-title":"Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib227","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jhep.2020.01.013","article-title":"NAFLD as a driver of chronic kidney disease","volume":"72","author":"Byrne","year":"2020","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib228","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1186\/s12872-023-03580-6","article-title":"The association between metabolic dysfunction-associated steatotic liver disease, cardiovascular and cerebrovascular diseases and the thickness of carotid plaque","volume":"23","author":"Huang","year":"2023","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jhep.2024.04.031_bib229","article-title":"Liver fibrosis, NT-ProBNP and mortality in patients with MASLD: a population-based cohort study","author":"Ciardullo","year":"2023","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"7","key":"10.1016\/j.jhep.2024.04.031_bib230","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/apt.14937","article-title":"Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases","volume":"48","author":"Stine","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib231","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jhep.2013.08.011","article-title":"Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team","volume":"60","author":"Dyson","year":"2014","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.jhep.2024.04.031_bib232","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/apt.14261","article-title":"Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period","volume":"46","author":"Pais","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.jhep.2024.04.031_bib233","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1007\/s00535-011-0431-9","article-title":"Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey","volume":"46","author":"Tokushige","year":"2011","journal-title":"J Gastroenterol"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib234","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.cgh.2011.01.023","article-title":"Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma","volume":"9","author":"Yasui","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib235","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s12072-015-9679-0","article-title":"Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis","volume":"10","author":"Mohamad","year":"2016","journal-title":"Hepatol Int"},{"issue":"10","key":"10.1016\/j.jhep.2024.04.031_bib236","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1007\/s10620-015-3821-7","article-title":"Hepatocellular carcinoma in the setting of non-cirrhotic nonalcoholic fatty liver disease and the metabolic syndrome: US experience","volume":"60","author":"Perumpail","year":"2015","journal-title":"Dig Dis Sci"},{"issue":"10","key":"10.1016\/j.jhep.2024.04.031_bib237","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.14309\/ajg.0000000000000715","article-title":"Cost-effectiveness of hepatocellular carcinoma surveillance: an assessment of benefits and harms","volume":"115","author":"Parikh","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib238","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0002-9343(96)00197-0","article-title":"Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis","volume":"101","author":"Sarasin","year":"1996","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib239","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.cgh.2021.05.002","article-title":"Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression","volume":"20","author":"Orci","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib240","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jhep.2021.08.012","article-title":"Epidemiology and risk-stratification of NAFLD-associated HCC","volume":"75","author":"Ioannou","year":"2021","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.jhep.2024.04.031_bib241","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cgh.2012.10.001","article-title":"Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review","volume":"10","author":"White","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib242","doi-asserted-by":"crossref","DOI":"10.1097\/TP.0000000000002361","article-title":"Should patients with NAFLD\/NASH Be surveyed for HCC?","volume":"103","author":"Reig","year":"2019","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.jhep.2024.04.031_bib243","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000183","article-title":"Incidence of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis or advanced liver fibrosis","volume":"7","author":"Behari","year":"2023","journal-title":"Hepatol Commun"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib244","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","article-title":"Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease","volume":"155","author":"Kanwal","year":"2018","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib245","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1002\/hep.29660","article-title":"Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: results from two prospective cohort studies","volume":"67","author":"Simon","year":"2018","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib246","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib248","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/apt.13505","article-title":"Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer","volume":"43","author":"Walker","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib249","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.31309","article-title":"Use of hepatocellular carcinoma surveillance in patients with cirrhosis: a systematic review and meta-analysis","volume":"73","author":"Wolf","year":"2021","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib250","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1053\/j.gastro.2018.01.064","article-title":"Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis","volume":"154","author":"Tzartzeva","year":"2018","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib251","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/hep.28895","article-title":"An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis","volume":"65","author":"Atiq","year":"2017","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib252","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1001\/jamaoncol.2016.3147","article-title":"MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma","volume":"3","author":"Kim","year":"2017","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib253","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/hep.30330","article-title":"Magnetic resonance imaging is cost-effective for hepatocellular carcinoma surveillance in high-risk patients with cirrhosis","volume":"69","author":"Kim","year":"2019","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib254","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.cgh.2020.04.084","article-title":"Serum levels of \u03b1-fetoprotein increased more than 10 Years before detection of hepatocellular carcinoma","volume":"19","author":"Hughes","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib255","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2022.10.035","article-title":"Longitudinal changes in fibrosis\u00a0markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease","volume":"78","author":"Cholankeril","year":"2023","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib256","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/hep.29607","article-title":"Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science","volume":"67","author":"Siddiqui","year":"2018","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"8","key":"10.1016\/j.jhep.2024.04.031_bib257","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/j.cgh.2023.03.042","article-title":"Noninvasive assessment of liver fibrosis in NAFLD","volume":"21","author":"Sanyal","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib258","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jhep.2019.04.019","article-title":"Report on the AASLD\/EASL joint workshop on clinical trial endpoints in NAFLD","volume":"71","author":"Rinella","year":"2019","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib259","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/hep.32204","article-title":"Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis","volume":"75","author":"Sanyal","year":"2022","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"10","key":"10.1016\/j.jhep.2024.04.031_bib260","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.12565","article-title":"Association of histologic disease activity with progression of nonalcoholic fatty liver disease","volume":"2","author":"Kleiner","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib261","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/hep.30418","article-title":"Improvements in histologic features and diagnosis associated with improvement in fibrosis in nonalcoholic steatohepatitis: results from the nonalcoholic steatohepatitis clinical research network treatment trials","volume":"70","author":"Brunt","year":"2019","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"11","key":"10.1016\/j.jhep.2024.04.031_bib262","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.cgh.2020.08.061","article-title":"Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis","volume":"19","author":"Stine","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib263","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/gutjnl-2021-324264","article-title":"Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease","volume":"71","author":"Tamaki","year":"2022","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib264","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/hep.30590","article-title":"NGM282 improves liver fibrosis and histology in 12 Weeks in patients with nonalcoholic steatohepatitis","volume":"71","author":"Harrison","year":"2020","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib265","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.31108","article-title":"Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study","volume":"72","author":"Ratziu","year":"2020","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"11","key":"10.1016\/j.jhep.2024.04.031_bib266","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib267","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2021.10.029","article-title":"Non-invasive evaluation of response to obeticholic acid in patients with NASH: results from the REGENERATE study","volume":"76","author":"Rinella","year":"2022","journal-title":"J Hepatol"},{"issue":"10213","key":"10.1016\/j.jhep.2024.04.031_bib268","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib269","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jhep.2018.09.024","article-title":"Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: analysis of data from a phase II trial of selonsertib","volume":"70","author":"Jayakumar","year":"2019","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib270","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jhep.2019.09.018","article-title":"Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis","volume":"72","author":"Bril","year":"2020","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib271","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2018.09.021","article-title":"Factors associated with histologic response in adult patients with nonalcoholic steatohepatitis","volume":"156","author":"Loomba","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.04.031_bib272","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102310","article-title":"FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"66","author":"Wai-Sun Wong","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib273","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41591-019-0379-5","article-title":"Platelet GPIbalpha is a mediator and potential interventional target for NASH and subsequent liver cancer","volume":"25","author":"Malehmir","year":"2019","journal-title":"Nat Med"},{"issue":"13","key":"10.1016\/j.jhep.2024.04.031_bib274","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1016\/j.cgh.2019.04.061","article-title":"Daily aspirin use associated with\u00a0reduced risk for fibrosis progression in patients with nonalcoholic fatty\u00a0liver disease","volume":"17","author":"Simon","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.04.031_bib275","article-title":"Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults","volume":"367","author":"Alexander","year":"2019","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.jhep.2024.04.031_bib276","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41575-018-0010-0","article-title":"Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease","volume":"15","author":"Anstee","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib277","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0263931","article-title":"Lifestyle changes in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"17","author":"Fernandez","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2024.04.031_bib278","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154455","article-title":"The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"115","author":"Koutoukidis","year":"2021","journal-title":"Metabolism"},{"issue":"9","key":"10.1016\/j.jhep.2024.04.031_bib279","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.clnu.2022.06.037","article-title":"The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis","volume":"41","author":"Haigh","year":"2022","journal-title":"Clin Nutr"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib280","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.jhep.2024.04.031_bib281","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1016\/j.cgh.2021.01.023","article-title":"Weight loss and weight regain in usual clinical practice: results from the TARGET-NASH observational cohort","volume":"20","author":"Malespin","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"31","key":"10.1016\/j.jhep.2024.04.031_bib282","doi-asserted-by":"crossref","first-page":"E875","DOI":"10.1503\/cmaj.191707","article-title":"Obesity in adults: a clinical practice guideline","volume":"192","author":"Wharton","year":"2020","journal-title":"CMAJ"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib283","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cmet.2022.12.001","article-title":"Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: a randomized controlled trial","volume":"35","author":"Ezpeleta","year":"2023","journal-title":"Cell Metab."},{"issue":"11","key":"10.1016\/j.jhep.2024.04.031_bib284","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41575-023-00800-4","article-title":"Lifestyle interventions in nonalcoholic fatty liver disease","volume":"20","author":"Younossi","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib285","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1055\/s-0041-1723751","article-title":"Effects of mediterranean diet in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression analysis of randomized controlled trials","volume":"41","author":"Kawaguchi","year":"2021","journal-title":"Semin Liver Dis"},{"issue":"7","key":"10.1016\/j.jhep.2024.04.031_bib286","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1111\/liv.14818","article-title":"Effects of two personalized dietary strategies during a 2-year intervention in subjects with nonalcoholic fatty liver disease: a randomized trial","volume":"41","author":"Marin-Alejandre","year":"2021","journal-title":"Liver Int"},{"issue":"11","key":"10.1016\/j.jhep.2024.04.031_bib287","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1136\/gutjnl-2020-323106","article-title":"Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial","volume":"70","author":"Yaskolka","year":"2021","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib288","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.3513","article-title":"Effects of time-restricted eating on nonalcoholic fatty liver disease: the TREATY-FLD randomized clinical trial","volume":"6","author":"Wei","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"11","key":"10.1016\/j.jhep.2024.04.031_bib289","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41575-021-00472-y","article-title":"Dietary carbohydrates and fats in nonalcoholic fatty liver disease","volume":"18","author":"Yki-J\u00e4rvinen","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib290","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M22-1787","article-title":"Effect of calorie-unrestricted low-carbohydrate, high-fat diet versus high-carbohydrate, low-fat diet on type 2 diabetes and nonalcoholic fatty liver disease : a randomized controlled trial","volume":"176","author":"Hansen","year":"2023","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.jhep.2024.04.031_bib291","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1111\/liv.15335","article-title":"One size does not fit all; practical, personal tailoring of the diet to NAFLD patients","volume":"42","author":"Zelber-Sagi","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2024.04.031_bib292","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2021.702802","article-title":"Ketogenic diets and chronic disease: weighing the benefits against the risks","volume":"8","author":"Crosby","year":"2021","journal-title":"Front Nutr"},{"issue":"10","key":"10.1016\/j.jhep.2024.04.031_bib293","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.3390\/nu11102442","article-title":"Effectiveness of intermittent fasting and time-restricted feeding compared to continuous energy restriction for weight loss","volume":"11","author":"Rynders","year":"2019","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib294","article-title":"Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet - a randomised controlled trial","volume":"3","author":"Holmer","year":"2021","journal-title":"JHEP Rep"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib295","article-title":"Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis","volume":"6","author":"Buzzetti","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib296","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/jgh.15363","article-title":"Relationship between dietary patterns and non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"36","author":"Hassani","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib297","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jhep.2019.04.013","article-title":"The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content","volume":"71","author":"Gepner","year":"2019","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib298","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/hep.30076","article-title":"Ad libitum mediterranean and low-fat diets both significantly reduce hepatic steatosis: a randomized controlled trial","volume":"68","author":"Properzi","year":"2018","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib299","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0007114520000914","article-title":"Food groups and the likelihood of non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"124","author":"He","year":"2020","journal-title":"Br J Nutr"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib300","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12902-022-01015-5","article-title":"Lifestyle as well as metabolic syndrome and non-alcoholic fatty liver disease: an umbrella review of evidence from observational studies and randomized controlled trials","volume":"22","author":"Peng","year":"2022","journal-title":"BMC Endocr Disord"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib301","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1017\/S0007114522003956","article-title":"Association between ultra-processed foods consumption and risk of non-alcoholic fatty liver disease: a population-based analysis of NHANES 2011-2018","volume":"130","author":"Liu","year":"2023","journal-title":"Br J Nutr"},{"key":"10.1016\/j.jhep.2024.04.031_bib302","article-title":"Mortality from different causes associated with meat, heme iron, nitrates, and nitrites in the NIH-AARP Diet and Health Study: population based cohort study","volume":"357","author":"Etemadi","year":"2017","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib303","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jhep.2018.01.015","article-title":"High red and processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistance","volume":"68","author":"Zelber-Sagi","year":"2018","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib304","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1002\/hep.30967","article-title":"Diet associations with nonalcoholic fatty liver disease in an ethnically diverse population: the multiethnic cohort","volume":"71","author":"Noureddin","year":"2020","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib305","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/ajcn\/nqaa332","article-title":"Effects of fructose restriction on liver steatosis (FRUITLESS); a double-blind randomized controlled trial","volume":"113","author":"Simons","year":"2021","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib306","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jhep.2021.02.027","article-title":"Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial","volume":"75","author":"Geidl-Flueck","year":"2021","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.jhep.2024.04.031_bib307","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1016\/j.cgh.2021.11.001","article-title":"Sugar-sweetened beverage, diet\u00a0soda, and nonalcoholic fatty liver disease over 6 Years: the framingham\u00a0heart study","volume":"20","author":"Park","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib308","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jhep.2016.12.025","article-title":"Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents","volume":"66","author":"Mosca","year":"2017","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.jhep.2024.04.031_bib309","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.14309\/ajg.0000000000002222","article-title":"Significant dose-response association of physical activity and diet quality with mortality in adults with suspected NAFLD in a population study","volume":"118","author":"Vilar-Gomez","year":"2023","journal-title":"Am J Gastroenterol"},{"issue":"23","key":"10.1016\/j.jhep.2024.04.031_bib310","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1161\/CIR.0000000000001031","article-title":"2021 Dietary guidance to improve cardiovascular health: a scientific statement from the American heart association","volume":"144","author":"Lichtenstein","year":"2021","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib311","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1002\/hep.31158","article-title":"Inadequate physical activity and sedentary behavior are independent predictors of nonalcoholic fatty liver disease","volume":"72","author":"Kim","year":"2020","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib312","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000108","article-title":"American College of Sports Medicine (ACSM) International Multidisciplinary Roundtable report on physical activity and nonalcoholic fatty liver disease","volume":"7","author":"Stine","year":"2023","journal-title":"Hepatol Commun"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib313","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/1753-0407.13086","article-title":"Effect of exercise on hepatic steatosis: are benefits seen without dietary intervention? A systematic review and meta-analysis","volume":"13","author":"Baker","year":"2021","journal-title":"J Diabetes"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib314","article-title":"Weight-loss-independent benefits of exercise on liver steatosis and stiffness in Japanese men with NAFLD","volume":"3","author":"Oh","year":"2021","journal-title":"JHEP Rep"},{"issue":"9","key":"10.1016\/j.jhep.2024.04.031_bib315","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1136\/gut.2011.242073","article-title":"Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss","volume":"60","author":"Hallsworth","year":"2011","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib316","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jhep.2016.08.023","article-title":"Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review","volume":"66","author":"Hashida","year":"2017","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib317","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1210\/clinem\/dgab795","article-title":"The effect of high-intensity interval\u00a0training vs moderate-intensity continuous training on liver fat: a systematic review and meta-analysis","volume":"107","author":"Sabag","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.jhep.2024.04.031_bib318","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/apt.15989","article-title":"Improvement in histological endpoints of MAFLD following a 12-week aerobic exercise intervention","volume":"52","author":"O\u2019Gorman","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.jhep.2024.04.031_bib319","doi-asserted-by":"crossref","DOI":"10.3390\/genes14091811","article-title":"Exercise does not independently improve histological outcomes in biopsy-proven non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"14","author":"Chen","year":"2023","journal-title":"Genes (Basel)"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib320","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/lt.24958","article-title":"Exercise and physical activity for patients with end-stage liver disease: improving functional status and sarcopenia while on the transplant waiting list","volume":"24","author":"Duarte-Rojo","year":"2018","journal-title":"Liver Transpl"},{"issue":"12","key":"10.1016\/j.jhep.2024.04.031_bib321","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000014918","article-title":"A randomized controlled trial on the effectiveness of 8-week high-intensity interval exercise on intrahepatic triglycerides, visceral lipids, and health-related quality of life in diabetic obese patients with nonalcoholic fatty liver disease","volume":"98","author":"Abdelbasset","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib322","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.cgh.2020.07.023","article-title":"Physical activity, measured objectively, is associated with lower mortality in patients with nonalcoholic fatty liver disease","volume":"19","author":"Kim","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib323","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.cgh.2021.12.043","article-title":"Association of physical activity with risk of liver fibrosis, sarcopenia, and cardiovascular disease in nonalcoholic fatty liver disease","volume":"21","author":"Chun","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib324","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/apt.17308","article-title":"Vigorous physical activity provides protection against all-cause deaths among adults patients with nonalcoholic fatty liver disease (NAFLD)","volume":"57","author":"Henry","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib325","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s10620-022-07601-w","article-title":"Physical activity and risk of hepatocellular carcinoma: a systematic review and meta-analysis","volume":"68","author":"DiJoseph","year":"2023","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib326","article-title":"Physical activity is inversely associated with hepatic fibro-inflammation: a population-based cohort study using UK Biobank data","volume":"5","author":"Sherry","year":"2023","journal-title":"JHEP Rep"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib327","article-title":"Non-alcoholic fatty liver disease: a patient guideline","volume":"3","author":"Francque","year":"2021","journal-title":"JHEP Rep"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib328","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jama.2023.10875","article-title":"Accelerometer-derived \"weekend warrior\" physical activity and incident cardiovascular disease","volume":"330","author":"Khurshid","year":"2023","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.jhep.2024.04.031_bib329","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"5","author":"Ye","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib330","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1053\/j.gastro.2022.06.023","article-title":"AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review","volume":"163","author":"Long","year":"2022","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib331","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1055\/s-0038-1677517","article-title":"NASH in lean individuals","volume":"39","author":"Younes","year":"2019","journal-title":"Semin Liver Dis"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib332","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/apt.14112","article-title":"Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients","volume":"46","author":"Sookoian","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib333","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jhep.2018.08.011","article-title":"Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease","volume":"69","author":"Wong","year":"2018","journal-title":"J Hepatol"},{"issue":"1S Suppl 1","key":"10.1016\/j.jhep.2024.04.031_bib334","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1097\/MEG.0000000000002158","article-title":"Weight change and resolution of fatty liver in normal weight individuals with nonalcoholic fatty liver disease","volume":"33","author":"Sinn","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.jhep.2024.04.031_bib335","first-page":"CD013157","article-title":"Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis","volume":"7","author":"Komolafe","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib336","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2023.2226922","article-title":"Targeting nonalcoholic fatty liver disease via gut microbiome-centered therapies","volume":"15","author":"Koning","year":"2023","journal-title":"Gut Microbes"},{"key":"10.1016\/j.jhep.2024.04.031_bib337","doi-asserted-by":"crossref","DOI":"10.1177\/1756284819878046","article-title":"Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"12","author":"Tang","year":"2019","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.jhep.2024.04.031_bib338","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2020.08.071","article-title":"The effect of coffee consumption on the non-alcoholic fatty liver disease and liver fibrosis: a meta-analysis of 11 epidemiological studies","volume":"20","author":"Hayat","year":"2021","journal-title":"Ann Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib339","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1016\/j.clnu.2018.11.030","article-title":"A systematic review and a dose-response meta-analysis of coffee dose and nonalcoholic fatty liver disease","volume":"38","author":"Chen","year":"2019","journal-title":"Clin Nutr"},{"issue":"9","key":"10.1016\/j.jhep.2024.04.031_bib340","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.cgh.2021.09.042","article-title":"Coffee consumption is associated with lower liver stiffness: a nationally representative study","volume":"20","author":"Niezen","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib341","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1186\/s12889-021-10991-7","article-title":"All coffee types decrease the risk of adverse clinical outcomes in chronic liver disease: a UK Biobank study","volume":"21","author":"Kennedy","year":"2021","journal-title":"BMC Public Health"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib342","first-page":"421","article-title":"Inverse association of coffee with liver cancer development: an updated systematic review and meta-analysis","volume":"29","author":"Bhurwal","year":"2020","journal-title":"J Gastrointestin Liver Dis"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib343","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12937-021-00694-5","volume":"20","author":"Mansour","year":"2021","journal-title":"Nutr J"},{"key":"10.1016\/j.jhep.2024.04.031_bib344","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.nutres.2022.07.010","article-title":"Coffee consumption has no effect on circulating markers of liver function but increases adiponectin concentrations: a systematic review and meta-analysis of randomized controlled trials","volume":"106","author":"Linden-Torres","year":"2022","journal-title":"Nutr Res"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib345","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cgh.2017.08.014","article-title":"Subclinical hypothyroidism and low-normal thyroid function are associated with nonalcoholic steatohepatitis and fibrosis","volume":"16","author":"Kim","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.jhep.2024.04.031_bib346","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.tem.2022.08.001","article-title":"NAFLD and thyroid function: pathophysiological and therapeutic considerations","volume":"33","author":"Hatziagelaki","year":"2022","journal-title":"Trends Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib347","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/hep.31296","article-title":"Thyroid hormone signaling and the liver","volume":"72","author":"Ritter","year":"2020","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"24","key":"10.1016\/j.jhep.2024.04.031_bib348","doi-asserted-by":"crossref","first-page":"E3451","DOI":"10.1073\/pnas.1506113113","article-title":"Thyroid hormones inhibit TGF-\u03b2 signaling and attenuate fibrotic responses","volume":"113","author":"Alonso-Merino","year":"2016","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"10","key":"10.1016\/j.jhep.2024.04.031_bib349","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1021\/jm4019299","volume":"57","author":"Kelly","year":"2014","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib350","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib351","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/apt.17734","article-title":"Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis","volume":"59","author":"Harrison","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib352","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jhep.2023.04.031","article-title":"NIS2+\u2122, an optimisation of the blood-based biomarker NIS4\u00ae technology for the detection of at-risk NASH: a prospective derivation and validation study","volume":"79","author":"Harrison","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.031_bib353","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S2468-1253(20)30252-1","article-title":"NIS4\u2122 for non-invasive diagnosis of nonalcoholic steatohepatitis and liver fibrosis","volume":"5","author":"Harrison","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.jhep.2024.04.031_bib354","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1038\/s41591-023-02539-6","article-title":"Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.jhep.2024.04.031_bib355","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1136\/gutjnl-2022-328689","article-title":"Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis","volume":"72","author":"Ravaioli","year":"2023","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib356","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.32145","article-title":"Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis","volume":"75","author":"Tamaki","year":"2022","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"10","key":"10.1016\/j.jhep.2024.04.031_bib357","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1016\/j.cgh.2023.02.003","article-title":"MRI-AST (MAST) score accurately predicts major adverse liver outcome, hepatocellular carcinoma, liver transplant, and liver-related death","volume":"21","author":"Truong","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib358","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jhep.2023.04.025","article-title":"An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography","volume":"79","author":"Liang","year":"2023","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.jhep.2024.04.031_bib359","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.cgh.2020.09.044","article-title":"Liver stiffness by magnetic resonance elastography predicts future cirrhosis, decompensation, and death in NAFLD","volume":"19","author":"Gidener","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib360","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/hep.30664","article-title":"The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials","volume":"70","author":"Sanyal","year":"2019","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib361","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.jhep.2024.04.031_bib362","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib363","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1056\/NEJMe2314365","article-title":"Selective agonists of thyroid hormone receptor beta for the treatment of NASH","volume":"390","author":"Cusi","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib364","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jhep.2023.04.003","article-title":"At the dawn of potent therapeutics for fatty liver disease - introducing the miniseries on promising pharmacological targets for NASH","volume":"79","author":"Ratziu","year":"2023","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib365","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1161\/CIRCRESAHA.119.314944","article-title":"Relationship between serum alpha-tocopherol and overall and cause-specific mortality","volume":"125","author":"Huang","year":"2019","journal-title":"Circ Res"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib366","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/advances\/nmy040","article-title":"Dietary antioxidants, circulating antioxidant concentrations, total antioxidant capacity, and risk of all-cause mortality: a systematic review and dose-response meta-analysis of prospective observational studies","volume":"9","author":"Jayedi","year":"2018","journal-title":"Adv Nutr"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib367","doi-asserted-by":"crossref","first-page":"927","DOI":"10.14309\/ajg.0000000000001726","article-title":"Dietary vitamin E intake is associated with a reduced risk of developing digestive diseases and nonalcoholic fatty liver disease","volume":"117","author":"Scorletti","year":"2022","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1016\/j.jhep.2024.04.031_bib368","doi-asserted-by":"crossref","first-page":"824","DOI":"10.7326\/0003-4819-159-12-201312170-00729","article-title":"Vitamin and mineral supplements in the primary prevention of cardiovascular disease and cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force","volume":"159","author":"Fortmann","year":"2013","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.jhep.2024.04.031_bib369","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074558","article-title":"Meta-regression analyses, meta-analyses, and trial sequential analyses of the effects of supplementation with beta-carotene, vitamin A, and vitamin E singly or in different combinations on all-cause mortality: do we have evidence for lack of harm?","volume":"8","author":"Bjelakovic","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2024.04.031_bib370","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f10","article-title":"Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials","volume":"346","author":"Myung","year":"2013","journal-title":"Bmj"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib371","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/hep.30368","article-title":"Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis","volume":"71","author":"Vilar-Gomez","year":"2020","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhep.2024.04.031_bib372","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib373","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/hep.20092","article-title":"Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial","volume":"39","author":"Lindor","year":"2004","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib374","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/hep.23727","article-title":"High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Leuschner","year":"2010","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib375","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jhep.2010.08.030","article-title":"A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis","volume":"54","author":"Ratziu","year":"2011","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib376","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jhep.2021.06.036","article-title":"24-Norursodeoxycholic acid reshapes immunometabolism in CD8(+) T cells and alleviates hepatic inflammation","volume":"75","author":"Zhu","year":"2021","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.jhep.2024.04.031_bib377","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2468-1253(19)30184-0","article-title":"Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial","volume":"4","author":"Traussnigg","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"17-18","key":"10.1016\/j.jhep.2024.04.031_bib378","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.drudis.2012.05.012","article-title":"Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis","volume":"17","author":"Adorini","year":"2012","journal-title":"Drug Discov Today"},{"issue":"7","key":"10.1016\/j.jhep.2024.04.031_bib379","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"issue":"9972","key":"10.1016\/j.jhep.2024.04.031_bib380","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"issue":"10215","key":"10.1016\/j.jhep.2024.04.031_bib381","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib382","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jhep.2023.07.014","article-title":"Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis","volume":"79","author":"Sanyal","year":"2023","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib383","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jhep.2021.10.018","article-title":"EDP-305 in patients with NASH: a phase II double-blind placebo-controlled dose-ranging study","volume":"76","author":"Ratziu","year":"2022","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib384","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jhep.2022.10.023","article-title":"Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH","volume":"78","author":"Ratziu","year":"2023","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib385","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/hep.21763","article-title":"A lipidomic analysis of nonalcoholic fatty liver disease","volume":"46","author":"Puri","year":"2007","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib386","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/j.gastro.2014.04.046","article-title":"No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial","volume":"147","author":"Sanyal","year":"2014","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib387","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jhep.2014.08.036","article-title":"Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial","volume":"62","author":"Argo","year":"2015","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib388","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2021.12.004","article-title":"A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH","volume":"76","author":"Fraser","year":"2022","journal-title":"J Hepatol"},{"issue":"9756","key":"10.1016\/j.jhep.2024.04.031_bib389","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","article-title":"Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis","volume":"376","author":"Athyros","year":"2010","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jhep.2024.04.031_bib390","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1210\/jc.2017-00867","article-title":"Liver safety of statins\u00a0in\u00a0prediabetes or T2DM and nonalcoholic steatohepatitis: post\u00a0hoc\u00a0analysis of a randomized trial","volume":"102","author":"Bril","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib391","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1053\/j.gastro.2004.02.015","article-title":"Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity","volume":"126","author":"Chalasani","year":"2004","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib392","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1007\/s10620-015-4000-6","article-title":"Statins are underutilized in patients with nonalcoholic fatty liver disease and dyslipidemia","volume":"61","author":"Blais","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2024.04.031_bib393","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104392","article-title":"Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study","volume":"87","author":"Ayada","year":"2023","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib394","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1053\/j.gastro.2009.01.053","article-title":"Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes","volume":"136","author":"El-Serag","year":"2009","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.jhep.2024.04.031_bib395","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.cgh.2017.04.016","article-title":"A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis","volume":"15","author":"Wah Kheong","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.jhep.2024.04.031_bib396","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221683","article-title":"Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: a randomized, double-blind, placebo controlled trial","volume":"14","author":"Navarro","year":"2019","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib397","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jhep.2023.07.033","article-title":"Incretins (GLP-1 receptor agonists and dual\/triple agonists) and the liver","volume":"79","author":"Newsome","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.031_bib398","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol Metab"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib399","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/s42255-023-00812-z","article-title":"Gut hormone co-agonists for the treatment of obesity: from bench to bedside","volume":"5","author":"Nogueiras","year":"2023","journal-title":"Nat Metab"},{"key":"10.1016\/j.jhep.2024.04.031_bib400","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jhep.2024.04.031_bib401","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib402","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","article-title":"Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial","volume":"77","author":"Alkhouri","year":"2022","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib403","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib404","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib405","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/dc20-2151","article-title":"Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study","volume":"44","author":"Nahra","year":"2021","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib406","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease","volume":"79","author":"Romero-Gomez","year":"2023","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib407","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00125-023-06053-9","article-title":"Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon\/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial","volume":"67","author":"Bluher","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.jhep.2024.04.031_bib408","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib409","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.cgh.2021.07.010","article-title":"Glucagon-like peptide-1 receptor agonists and hepatic decompensation events in patients with cirrhosis and diabetes","volume":"20","author":"Simon","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.04.031_bib410","article-title":"Glucagon-like peptide-1 receptor agonist use in patients with liver cirrhosis and type 2 diabetes","author":"Yen","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib411","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10296","key":"10.1016\/j.jhep.2024.04.031_bib412","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jhep.2024.04.031_bib413","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(14)70120-2","article-title":"Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial","volume":"2","author":"Ridderstr\u00e5le","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.jhep.2024.04.031_bib414","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib415","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib416","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2337\/dc18-1569","article-title":"The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients","volume":"42","author":"Latva-Rasku","year":"2019","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.jhep.2024.04.031_bib417","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-022-01861-9","article-title":"Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study","volume":"28","author":"Harrison","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib418","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib419","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"issue":"22","key":"10.1016\/j.jhep.2024.04.031_bib420","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"issue":"9493","key":"10.1016\/j.jhep.2024.04.031_bib421","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.jhep.2024.04.031_bib422","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib423","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jhep.2023.07.004","article-title":"Treating NASH by targeting peroxisome proliferator-activated receptors","volume":"79","author":"Staels","year":"2023","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib424","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jhep.2023.02.004","article-title":"Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: a phase II randomized placebo-controlled trial (DESTINY-1)","volume":"78","author":"Harrison","year":"2023","journal-title":"J Hepatol"},{"issue":"17","key":"10.1016\/j.jhep.2024.04.031_bib425","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib426","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib427","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-78342-x","article-title":"Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study","volume":"10","author":"Goyal","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib428","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2036.2004.02025.x","article-title":"Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial","volume":"20","author":"Nair","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib429","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1365-2036.2008.03869.x","article-title":"Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis","volume":"29","author":"Loomba","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib430","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/apt.15331","article-title":"Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis","volume":"50","author":"Vilar-Gomez","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib431","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jhep.2017.09.016","article-title":"Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine","volume":"68","author":"Fujiwara","year":"2018","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib432","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/hep.27199","article-title":"Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes","volume":"60","author":"Zhang","year":"2014","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib433","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2022.08.045","article-title":"AGA clinical practice guideline on pharmacological interventions for adults with obesity","volume":"163","author":"Grunvald","year":"2022","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib434","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/hep.22575","article-title":"Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial","volume":"49","author":"Harrison","year":"2009","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib435","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1007\/s00464-020-07555-y","article-title":"Clinical practice guidelines of the European Association for Endoscopic Surgery (EAES) on bariatric surgery: update 2020 endorsed by IFSO-EC, EASO and ESPCOP","volume":"34","author":"Di Lorenzo","year":"2020","journal-title":"Surg Endosc"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib436","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2337\/dc15-0575","article-title":"Determinants of diabetes remission and glycemic control after bariatric surgery","volume":"39","author":"Panunzi","year":"2016","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.jhep.2024.04.031_bib437","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.35003","article-title":"Association of bariatric surgery with cardiovascular outcomes in adults with severe obesity and nonalcoholic fatty liver disease","volume":"5","author":"Elsaid","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib438","doi-asserted-by":"crossref","first-page":"444","DOI":"10.2337\/dc21-1335","article-title":"Association of bariatric surgery with cancer incidence in patients with obesity and diabetes: long-term results from the Swedish obese subjects study","volume":"45","author":"Sj\u00f6holm","year":"2022","journal-title":"Diabetes Care"},{"issue":"20","key":"10.1016\/j.jhep.2024.04.031_bib439","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1001\/jama.2021.19569","article-title":"Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis","volume":"326","author":"Aminian","year":"2021","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib440","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.soard.2018.12.002","article-title":"Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis","volume":"15","author":"Fakhry","year":"2019","journal-title":"Surg Obes Relat Dis"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib441","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1007\/s11695-022-06011-1","article-title":"Bariatric surgery improves nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"32","author":"Zhou","year":"2022","journal-title":"Obes Surg"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib442","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/hep.32358","article-title":"Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery","volume":"76","author":"Pais","year":"2022","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib443","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterology"},{"issue":"10390","key":"10.1016\/j.jhep.2024.04.031_bib444","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/S0140-6736(23)00634-7","article-title":"Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial","volume":"401","author":"Verrastro","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2024.04.031_bib445","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.931519","article-title":"Effects of bariatric endoscopy on non-alcoholic fatty liver disease: a comprehensive systematic review and meta-analysis","volume":"13","author":"Ren","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib446","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/hep.32049","article-title":"Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 practice guidance by the American association for the study of liver diseases","volume":"74","author":"Lai","year":"2021","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib447","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.clnu.2018.12.022","article-title":"ESPEN guideline on clinical nutrition in liver disease","volume":"38","author":"Plauth","year":"2019","journal-title":"Clin Nutr"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib448","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jhep.2017.11.030","article-title":"A model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: a competing risk analysis in a national cohort","volume":"68","author":"van Vugt","year":"2018","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib449","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jhep.2018.06.024","article-title":"EASL Clinical Practice Guidelines on nutrition in chronic liver disease","volume":"70","year":"2019","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib450","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/jcsm.12039","article-title":"Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis","volume":"7","author":"Montano-Loza","year":"2016","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib451","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.clnu.2021.11.014","article-title":"Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement","volume":"41","author":"Donini","year":"2022","journal-title":"Clin Nutr"},{"issue":"11","key":"10.1016\/j.jhep.2024.04.031_bib452","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.nut.2013.05.016","article-title":"Nutrition therapy using a multidisciplinary team improves survival rates in patients with liver cirrhosis","volume":"29","author":"Iwasa","year":"2013","journal-title":"Nutrition"},{"issue":"11","key":"10.1016\/j.jhep.2024.04.031_bib453","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1111\/jgh.16266","article-title":"Nutritional therapy for persistent cognitive impairment after resolution of overt hepatic encephalopathy in patients with cirrhosis: a double-blind randomized controlled trial","volume":"38","author":"Sharma","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib454","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/jgh.16035","article-title":"Home-based intensive nutrition therapy improves frailty and sarcopenia in patients with decompensated cirrhosis: a randomized clinical trial","volume":"38","author":"Meena","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib455","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/hep.28992","article-title":"Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: the SportDiet study","volume":"65","author":"Berzigotti","year":"2017","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib456","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.clnu.2023.03.021","article-title":"Practical guideline on obesity care in patients with gastrointestinal and liver diseases - joint ESPEN\/UEG guideline","volume":"42","author":"Bischoff","year":"2023","journal-title":"Clin Nutr"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib457","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/hep.22367","article-title":"Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial","volume":"48","author":"Plank","year":"2008","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib458","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1440-1746.2011.06951.x","article-title":"Late evening snack: exploiting a period of anabolic opportunity in cirrhosis","volume":"27","author":"Tsien","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.jhep.2024.04.031_bib459","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.14309\/ajg.0000000000001883","article-title":"Outcomes of exercise interventions in patients with advanced liver disease: a systematic review\u00a0of randomized clinical trials","volume":"117","author":"Jamali","year":"2022","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib460","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.cgh.2019.07.058","article-title":"Resistance training increases muscle strength and muscle size in patients with liver cirrhosis","volume":"18","author":"Aamann","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.jhep.2024.04.031_bib461","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.3390\/ijerph10083409","article-title":"Relationship between retinal vascular caliber and coronary artery disease in patients with non-alcoholic fatty liver disease (NAFLD)","volume":"10","author":"Josef","year":"2013","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib462","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jhep.2022.09.019","article-title":"Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan","volume":"78","author":"Tsai","year":"2023","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib463","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/hep.32294","article-title":"Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease","volume":"76","author":"Zhang","year":"2022","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"Pt 3","key":"10.1016\/j.jhep.2024.04.031_bib464","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1042\/bj3480607","article-title":"Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain","volume":"348","author":"Owen","year":"2000","journal-title":"Biochem J"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib465","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.352","article-title":"Association of metformin use on metabolic acidosis in diabetic patients with chronic hepatitis B-related cirrhosis and renal impairment","volume":"4","author":"Yip","year":"2021","journal-title":"Health Sci Rep"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib466","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3810\/pgm.2012.07.2574","article-title":"Managing diabetes in patients with chronic liver disease","volume":"124","author":"Khan","year":"2012","journal-title":"Postgrad Med"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib467","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1055\/s-2002-30102","article-title":"Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs","volume":"22","author":"Chitturi","year":"2002","journal-title":"Semin Liver Dis"},{"issue":"10","key":"10.1016\/j.jhep.2024.04.031_bib468","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/j.cgh.2020.05.021","article-title":"SGLT2 inhibitors in liver patients","volume":"18","author":"Hsiang","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib469","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/MEG.0000000000002517","article-title":"Statin can reduce the risk of hepatocellular carcinoma among patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"35","author":"Zhang","year":"2023","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib470","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jhep.2007.02.013","article-title":"Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study","volume":"47","author":"Ekstedt","year":"2007","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib471","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1053\/j.gastro.2016.01.004","article-title":"Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis","volume":"150","author":"Abraldes","year":"2016","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib472","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S2468-1253(19)30320-6","article-title":"Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"5","author":"Pose","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib473","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib474","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.cgh.2012.09.025","article-title":"Association between anthropometric parameters and measurements of liver stiffness by transient elastography","volume":"11","author":"Wong","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib475","doi-asserted-by":"crossref","first-page":"723","DOI":"10.14309\/ajg.0000000000000994","article-title":"Noninvasive diagnosis of portal hypertension in patients with compensated advanced chronic liver disease","volume":"116","author":"Pons","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"10181","key":"10.1016\/j.jhep.2024.04.031_bib476","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"Beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial","volume":"393","author":"Villanueva","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jhep.2024.04.031_bib477","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.cgh.2019.04.062","article-title":"Performance of Baveno VI and expanded Baveno VI criteria for excluding high-risk varices in patients with chronic liver diseases: a systematic review and meta-analysis","volume":"17","author":"Stafylidou","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib478","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.jhep.2018.05.019","article-title":"Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis","volume":"69","author":"Petta","year":"2018","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib479","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1007\/s00330-020-07223-8","article-title":"Diagnostic accuracy of spleen stiffness to evaluate portal hypertension and esophageal varices in chronic liver disease: a systematic review and meta-analysis","volume":"31","author":"Hu","year":"2021","journal-title":"Eur Radiol"},{"issue":"9","key":"10.1016\/j.jhep.2024.04.031_bib480","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S2468-1253(23)00150-4","article-title":"Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a systematic review and individual patient data meta-analysis","volume":"8","author":"Dajti","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib481","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jhep.2022.10.030","article-title":"Baveno VII algorithm outperformed other models in ruling out high-risk varices in individuals with HBV-related cirrhosis","volume":"78","author":"Zhang","year":"2023","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib482","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jhep.2019.04.011","article-title":"Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European Liver Transplant Registry study","volume":"71","author":"Haldar","year":"2019","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib483","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1007\/s12072-022-10414-8","article-title":"The clinical implications of pre-liver transplant diabetes on post-liver transplant outcomes in patients with NASH: analysis of the UNOS database","volume":"16","author":"Lee","year":"2022","journal-title":"Hepatol Int"},{"issue":"8 Pt A","key":"10.1016\/j.jhep.2024.04.031_bib484","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1053\/j.jvca.2021.07.020","article-title":"Management of patients with non-alcoholic steatohepatitis undergoing liver transplantation: considerations for the anesthesiologist","volume":"36","author":"Sharma","year":"2022","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib485","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/hep.25855","article-title":"Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events","volume":"56","author":"Vanwagner","year":"2012","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib486","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/LVT.0000000000000007","article-title":"Outcomes in liver transplant recipients with nonalcoholic fatty liver disease-related HCC: results from the US multicenter HCC transplant consortium","volume":"29","author":"Verna","year":"2023","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2024.04.031_bib487","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2022.106752","article-title":"Clinical evidence of outcomes following\u00a0liver transplantation in patients with nonalcoholic steatohepatitis: an updated meta-analysis and systematic review","volume":"104","author":"Zhou","year":"2022","journal-title":"Int J Surg"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib488","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jhep.2023.03.023","article-title":"Evaluation of recipients with significant comorbidity - patients with cardiovascular disease","volume":"78","author":"Tsochatzis","year":"2023","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib489","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/TP.0000000000002433","article-title":"International liver transplantation consensus statement on end-stage liver disease due to nonalcoholic steatohepatitis and liver transplantation","volume":"103","author":"Tsochatzis","year":"2019","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib490","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1002\/hep.29329","article-title":"A point-based prediction model for cardiovascular risk in orthotopic liver transplantation: the CAR-OLT score","volume":"66","author":"VanWagner","year":"2017","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib491","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13229","article-title":"Cardio-hepatic risk assessment by CMR imaging in liver transplant candidates","volume":"32","author":"Reddy","year":"2018","journal-title":"Clin Transpl"},{"issue":"11","key":"10.1016\/j.jhep.2024.04.031_bib492","doi-asserted-by":"crossref","first-page":"877","DOI":"10.4254\/wjh.v10.i11.877","article-title":"Cardiac stress testing and coronary artery disease in liver transplantation candidates: meta-analysis","volume":"10","author":"Soldera","year":"2018","journal-title":"World J Hepatol"},{"issue":"10","key":"10.1016\/j.jhep.2024.04.031_bib493","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1097\/TP.0000000000001794","article-title":"Liver transplantation in the obese cirrhotic patient","volume":"101","author":"Spengler","year":"2017","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib494","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/SLA.0b013e31818a01ef","article-title":"Prolonged waiting times for liver transplantation in obese patients","volume":"248","author":"Segev","year":"2008","journal-title":"Ann Surg"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib495","first-page":"646","article-title":"Listing practices for morbidly obese patients at liver transplantation centers in the United States","volume":"14","author":"Halegoua-De Marzio","year":"2016","journal-title":"Exp Clin Transpl"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib496","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2023.03.014","article-title":"A proposal from the liver forum for the management of comorbidities in non-alcoholic steatohepatitis therapeutic trials","volume":"79","author":"Pais","year":"2023","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib497","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2015.10.006","article-title":"EASL clinical practice guidelines: liver transplantation","volume":"64","year":"2016","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib498","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1053\/j.gastro.2021.03.003","article-title":"AGA clinical practice guidelines on intragastric balloons in the management of obesity","volume":"160","author":"Muniraj","year":"2021","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib499","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.soard.2017.09.528","article-title":"Brazilian Intragastric Balloon Consensus Statement (BIBC): practical guidelines based on experience of over 40,000 cases","volume":"14","author":"Neto","year":"2018","journal-title":"Surg Obes Relat Dis"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib500","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.cgh.2020.10.034","article-title":"AGA clinical practice update on bariatric surgery in cirrhosis: expert review","volume":"19","author":"Patton","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib501","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s10620-022-07596-4","article-title":"Intragastric balloon in obese compensated nonalcoholic steatohepatitis cirrhosis patients is safe and achieves significant weight reduction at 6-months","volume":"68","author":"Vijayaraghavan","year":"2023","journal-title":"Dig Dis Sci"},{"issue":"9","key":"10.1016\/j.jhep.2024.04.031_bib502","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/lt.26074","article-title":"Efficacy and safety of endoscopic balloon placement for weight loss in patients with cirrhosis awaiting liver transplantation","volume":"27","author":"Watt","year":"2021","journal-title":"Liver Transpl"},{"issue":"10","key":"10.1016\/j.jhep.2024.04.031_bib503","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.cgh.2011.07.007","article-title":"Increased perioperative mortality following bariatric surgery among patients with cirrhosis","volume":"9","author":"Mosko","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib504","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/lt.25406","article-title":"Outcomes of sleeve gastrectomy in obese liver transplant candidates","volume":"25","author":"Sharpton","year":"2019","journal-title":"Liver Transpl"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib505","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/hep.29848","article-title":"Long-term outcomes of patients undergoing simultaneous liver transplantation and sleeve gastrectomy","volume":"68","author":"Zamora-Valdes","year":"2018","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"11","key":"10.1016\/j.jhep.2024.04.031_bib506","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1007\/s11695-022-06289-1","article-title":"Combined sleeve gastrectomy with liver transplant in patients with obesity: a feasibility study","volume":"32","author":"Gunturu","year":"2022","journal-title":"Obes Surg"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib507","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1600-6143.2012.04318.x","article-title":"Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease","volume":"13","author":"Heimbach","year":"2013","journal-title":"Am J Transpl"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib508","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/lt.26560","article-title":"Combined liver transplantation and sleeve gastrectomy: report of a brief-interval staged approach","volume":"29","author":"Tariq","year":"2023","journal-title":"Liver Transpl"},{"issue":"8","key":"10.1016\/j.jhep.2024.04.031_bib509","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/TP.0b013e31822e0bee","article-title":"Body composition and\u00a0overweight of liver transplant recipients","volume":"92","author":"Anast\u00e1cio","year":"2011","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib510","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jhep.2023.01.030","article-title":"Liver transplantation immunology: immunosuppression, rejection, and immunomodulation","volume":"78","author":"Montano-Loza","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.04.031_bib511","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154204","article-title":"Post-transplant obesity impacts long-term survival after liver transplantation","volume":"106","author":"van Son","year":"2020","journal-title":"Metabolism"},{"issue":"9","key":"10.1016\/j.jhep.2024.04.031_bib512","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S2468-1253(19)30181-5","article-title":"Management of metabolic syndrome and cardiovascular risk after liver transplantation","volume":"4","author":"Fatourou","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.jhep.2024.04.031_bib513","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1111\/ajt.13779","article-title":"Factors associated with major adverse cardiovascular events after liver transplantation among a national sample","volume":"16","author":"VanWagner","year":"2016","journal-title":"Am J Transpl"},{"issue":"7","key":"10.1016\/j.jhep.2024.04.031_bib514","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1097\/TP.0000000000002175","article-title":"Cardiovascular disease outcomes related to early stage renal impairment after liver transplantation","volume":"102","author":"VanWagner","year":"2018","journal-title":"Transplantation"},{"issue":"9","key":"10.1016\/j.jhep.2024.04.031_bib515","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/lt.23936","article-title":"Recurrent or de novo nonalcoholic fatty liver disease after liver transplantation: natural history based on liver biopsy analysis","volume":"20","author":"Vallin","year":"2014","journal-title":"Liver Transpl"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib516","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13000-022-01247-y","article-title":"Clinicopathologic features of de novo non-alcoholic steatohepatitis in the post-transplant setting","volume":"17","author":"Balitzer","year":"2022","journal-title":"Diagn Pathol"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib517","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/lt.25338","article-title":"Predictors of de novo nonalcoholic fatty liver disease after liver transplantation and associated fibrosis","volume":"25","author":"Galvin","year":"2019","journal-title":"Liver Transpl"},{"issue":"7","key":"10.1016\/j.jhep.2024.04.031_bib518","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001680","article-title":"Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis","volume":"11","author":"Musso","year":"2014","journal-title":"Plos Med"},{"issue":"7","key":"10.1016\/j.jhep.2024.04.031_bib519","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/MEG.0000000000001105","article-title":"De-novo nonalcoholic steatohepatitis is associated with long-term increased mortality in liver transplant recipients","volume":"30","author":"Gitto","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib520","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/ajt.15706","article-title":"Blood pressure control according to clinical practice guidelines is associated with decreased mortality and cardiovascular events among liver transplant recipients","volume":"20","author":"VanWagner","year":"2020","journal-title":"Am J Transpl"},{"issue":"10","key":"10.1016\/j.jhep.2024.04.031_bib521","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/lt.26219","article-title":"Metabolic complications in liver transplantation recipients: how we can optimize long-term survival","volume":"27","author":"Azhie","year":"2021","journal-title":"Liver Transpl"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib522","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/dom.13619","article-title":"Largest single-centre experience of dulaglutide for management of diabetes mellitus in solid organ transplant recipients","volume":"21","author":"Singh","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib523","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/TP.0000000000002147","article-title":"International liver transplantation society consensus statement on immunosuppression in liver transplant recipients","volume":"102","author":"Charlton","year":"2018","journal-title":"Transplantation"},{"issue":"11","key":"10.1016\/j.jhep.2024.04.031_bib524","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/lt.25637","article-title":"Delayed sleeve gastrectomy following liver\u00a0transplantation: a 5-year experience","volume":"25","author":"Morris","year":"2019","journal-title":"Liver Transpl"},{"issue":"2","key":"10.1016\/j.jhep.2024.04.031_bib525","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s11695-017-2847-7","article-title":"Laparoscopic sleeve gastrectomy for morbid obesity in patients after orthotopic liver transplant: a matched case-control study","volume":"28","author":"Tsamalaidze","year":"2018","journal-title":"Obes Surg"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib526","article-title":"NAFLD and liver transplantation: disease burden, current management and future challenges","volume":"2","author":"Burra","year":"2020","journal-title":"JHEP Rep"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib527","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","article-title":"EASL clinical practice guidelines: management of alcohol-related liver disease","volume":"69","year":"2018","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib528","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1017\/S0007114519003301","article-title":"A simple cut-off for waist-to-height ratio (0.5) can act as an indicator for cardiometabolic risk: recent data from adults in the Health Survey for England","volume":"123","author":"Gibson","year":"2020","journal-title":"Br J Nutr"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib529","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s11154-023-09796-3","article-title":"Relevance of body composition in phenotyping the obesities","volume":"24","author":"Salmon-Gomez","year":"2023","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"10.1016\/j.jhep.2024.04.031_bib530","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/HCO.0000000000001104","article-title":"Measuring lipoprotein (a) for cardiovascular disease prevention - in whom and when?","volume":"39","author":"Thomas","year":"2024","journal-title":"Curr Opin Cardiol"},{"issue":"14","key":"10.1016\/j.jhep.2024.04.031_bib531","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1016\/j.ejca.2012.02.063","article-title":"Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies","volume":"48","author":"Chen","year":"2012","journal-title":"Eur J Cancer"},{"issue":"36","key":"10.1016\/j.jhep.2024.04.031_bib532","doi-asserted-by":"crossref","first-page":"12945","DOI":"10.3748\/wjg.v20.i36.12945","article-title":"Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors","volume":"20","author":"Dongiovanni","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib533","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1002\/hep.29055","article-title":"Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review","volume":"65","author":"Ajmera","year":"2017","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib534","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2019.05.008","article-title":"Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification","volume":"71","author":"Ioannou","year":"2019","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2024.04.031_bib535","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jhep.2020.07.025","article-title":"aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis","volume":"73","author":"Fan","year":"2020","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.jhep.2024.04.031_bib536","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.gastha.2023.07.018","article-title":"Validation of noninvasive markers for HCC risk stratification in 1389 patients with biopsy-proven NAFLD","volume":"2","author":"Toyoda","year":"2023","journal-title":"Gastro Hep Adv"},{"issue":"3","key":"10.1016\/j.jhep.2024.04.031_bib537","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.cgh.2019.11.012","article-title":"GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis","volume":"18","author":"Best","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2024.04.031_bib538","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1053\/j.gastro.2023.06.027","article-title":"Incidence and risk factors for hepatocellular carcinoma in cirrhosis: the multicenter hepatocellular carcinoma early detection strategy (HEDS) study","volume":"165","author":"Reddy","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.04.031_bib539","article-title":"Toronto HCC risk index: a validated scoring system to predict 10-year risk of HCC in patients with cirrhosis","author":"Sharma","year":"2017","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2024.04.031_bib540","article-title":"External validation of the Toronto hepatocellular carcinoma risk index in a Swedish population","volume":"3","author":"Astrom","year":"2021","journal-title":"JHEP Rep"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824003295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824003295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T06:06:15Z","timestamp":1724393175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827824003295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":539,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0168827824003295"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier BV on behalf of European Association for the Study of the Liver (EASL) and by S Karger AG.","name":"copyright","label":"Copyright"}]}}